| Title: |
Precision Medicine in Angelman Syndrome. |
| Authors: |
Manssen, Lena1 (AUTHOR) lena.manssen@med.uni-muenchen.de, Krey, Ilona2 (AUTHOR), Gburek-Augustat, Janina3 (AUTHOR), von Hagen, Cornelia1,4 (AUTHOR), Lemke, Johannes R.2,5 (AUTHOR), Merkenschlager, Andreas3 (AUTHOR), Weigand, Heike1 (AUTHOR), Makowski, Christine1 (AUTHOR) |
| Source: |
Neuropediatrics. Apr2025, Vol. 56 Issue 2, p69-82. 14p. |
| Subject Terms: |
*SLEEP interruptions, *ANGELMAN syndrome, *INDIVIDUALIZED medicine, *THERAPEUTICS, *GENE expression |
| Abstract: |
Angelman syndrome (AS) is a rare neurogenetic disorder caused by a loss of function of UBE3A on the maternal allele. Clinical features include severe neurodevelopmental delay, epilepsy, sleep disturbances, and behavioral disorders. Therapy currently evolves from conventional symptomatic, supportive, and antiseizure treatments toward alteration of mRNA expression, which is subject of several ongoing clinical trials. This article will provide an overview of clinical research and therapeutic approaches on AS. [ABSTRACT FROM AUTHOR] |
|
Copyright of Neuropediatrics is the property of Georg Thieme Verlag Stuttgart and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
